NASDAQ:CYTK

Cytokinetics Stock Insider Trading

Healthcare > Biotechnology

Buy CYTK

*Your capital is at risk

$77.13

-3.29 (-4.09%)

At Close: Jul 31, 2026

Cytokinetics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -87.49. In total, the insiders bought 350.57K and sold 220.17K CYTK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-87.49
● Buy	350.57K shares
● Sell	220.17K shares
76% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Mar 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -87.49. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	9 307 Value: $412.9K
Jun 24, 2026 Sell	Common Stock S-Sale	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	38 730 Value: $3.19M
Jun 24, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	2 817 Value: $125.0K
Jun 24, 2026 Buy	Common Stock M-Exempt	Lee Sung EVP, Chief Financial Officer	C-Suite Officer	23 370 Value: $1.13M
Jun 23, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jun 23, 2026 Sell	Common Stock S-Sale	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $278.3K
Jun 23, 2026 Buy	Common Stock M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jun 15, 2026 Sell	Common Stock S-Sale	Blum Robert I President & CEO	CEO / President	7 500 Value: $528.5K
Jun 09, 2026 Buy	Common Stock M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jun 09, 2026 Sell	Common Stock S-Sale	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $237.9K
Jun 09, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Malik Fady Ibraham EVP Research & Development	Officer	3 500 Value: $27.3K
Jun 01, 2026 Sell	Common Stock S-Sale	Parshall B Lynne Director	Director	5 000 Value: $370.4K
Jun 01, 2026 Sell	Common Stock S-Sale	Kaye Edward M. Md Director	Director	2 933 Value: $223.2K
Jun 01, 2026 Buy	Non-Qualified Stock Option (Right to Buy) M-Exempt	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $348.9K
Jun 01, 2026 Sell	Common Stock S-Sale	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $1.11M
Jun 01, 2026 Buy	Common Stock M-Exempt	Callos Andrew EVP, Chief Commercial Officer	Officer	15 000 Value: $348.9K
May 27, 2026 Sell	Common Stock S-Sale	Blum Robert I President & CEO	CEO / President	7 500 Value: $579.1K
May 27, 2026 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Wysenski Nancy Director	Director	4 301 Value: $331.8K
May 27, 2026 Buy	Common Stock A-Award	Wierenga Wendell Director	Director	2 851 Value: $220.0K
May 27, 2026 Buy	Common Stock A-Award	Wysenski Nancy Director	Director	2 851 Value: $220.0K
May 27, 2026 Buy	Common Stock A-Award	Kaye Edward M. Md Director	Director	2 851 Value: $220.0K
May 27, 2026 Buy	Common Stock A-Award	Landry Robert E Director	Director	2 851 Value: $220.0K
May 27, 2026 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Harrington Robert Arthur Director	Director	4 301 Value: $331.8K
May 27, 2026 Buy	Common Stock A-Award	Henderson John T Director	Director	2 851 Value: $220.0K
May 27, 2026 Buy	Non-Qualified Stock Option (Right to Buy) A-Award	Bhanji Muna Director	Director	4 301 Value: $331.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYTOKINETICS

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...

Read Full Profile Here